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Abstract
Diabetic wounds remain a major medical challenge with often disappointing outcomes despite the best available care. An
impaired response to tissue hypoxia and insufficient angiogenesis are major factors responsible for poor healing in diabetic
wounds. Here we show that the antimycotic drug ciclopirox olamine (CPX) can induce therapeutic angiogenesis in diabetic
wounds. Treatment with CPX in vitro led to upregulation of multiple angiogenic genes and increased availability of HIF-1a.
Using an excisional wound splinting model in diabetic mice, we showed that serial topical treatment with CPX enhanced
wound healing compared to vehicle control treatment, with significantly accelerated wound closure, increased
angiogenesis, and increased dermal cellularity. These findings offer a promising new topical pharmacologic therapy for
the treatment of diabetic wounds.
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Introduction
Diabetic wounds are an area of increasing concern with the
epidemic proportions of diabetes incidence. In 2003, the number
of diabetic patients worldwide was already estimated at 197
million, and this number is projected to increase to 366 million by
2030 due to increased longevity [1]. Over 23 million people, or
7.8% of the US population, suffer from diabetes, and up to 25% of
all diabetics are estimated to develop a diabetic foot ulcer [2]. In
2004, approximately 71,000 nontraumatic lower-limb amputa-
tions were performed in diabetic patients[3]. The amputation of a
limb lends significant impact not only on patient’s quality of life
but also on patient mortality, with 5-year survival rate after a
lower-limb amputation of only 50% [2]. Nonhealing lower
extremity diabetic ulcers account for approximately 25–50% of
all hospital admissions in the diabetic population and are
responsible for the majority of resultant amputations [4].
A critical stimulus for normal wound healing is relative hypoxia,
and an impaired response to hypoxia could contribute to impaired
wound healing in diabetes [5]. Hypoxia-inducible factor (HIF)-1,
which is a heterodimeric transcription factor complex consisting of
hypoxia-stabilized a-subunit (HIF-1a) and a constitutively ex-
pressed b-subunit (HIF-1b), functions as a central regulator of
oxygen homeostasis. Under hypoxic conditions, stabilized HIF-1a
translocates to the nucleus, where it dimerizes with HIF-1b and
binds to a hypoxia response element (HRE) present on multiple
genes that are essential for cell survival during hypoxia [6]. HIF-1a
is critical for expression of multiple angiogenic growth factors, cell
motility, and recruitment of endothelial progenitor cells [7–9].
Prolyl hydroxylase domain (PHD)-2 is the key oxygen-dependent
negative regulator of the protein stability of HIF-1a [10]. Proline
hydroxylation serves as a critical step in determining the biological
half-life of HIF-1a, and transient silencing PHD-2 results in
normoxic stabilization of HIF-1a [11]. In addition, recent evidence
indicates that PHD-2 has an additional key physiological role
regulating angiogenesis through a HIF-independent mechanism
[10]. Thus, PHD-2 is a promising target for inducing therapeutic
angiogenesis for the treatment of chronic diabetic wounds.
While recombinant angiogenic growth factors and gene therapy
have been proposed as viable treatment modalities for therapeutic
angiogenesis, these modalities are hindered by many barriers to
mainstream medicine including safety concerns and high cost. A
pharmaceutical approach may be the most practical and beneficial
approach in the present considering its safety, cost, and ease of
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27844application. The antimycotic drug ciclopirox olamine (CPX) is a
bidentate iron chelator capable of inhibiting PHD-2 and activating
HIF-1a [12]. In this article, we evaluated whether the antimycotic
ciclopirox olamine (CPX) can be used as a topical treatment for
c h r o n i cd i a b e t i cw o u n d su s i n gad i a b e t i cm o u s ew o u n dm o d e l .O u r
novel findings using CPX, an already Federal Drug Administration
(FDA)approveddrugwitha safe side effectprofile,offerapromising
direction for the pharmacologic treatment of diabetic wounds.
Results
CPX is a potent inducer of HIF-1a stabilization and VEGF
expression
The effects of CPX on HIF-1a induction in mouse endothelial
cell line bEND.3 and in mouse fibroblast cell line NIH3T3 were
compared with deferoxamine (DFO), an iron-chelator well known
for HIF-1-inducing capabilities. The two cell lines were chosen to
simulate the types of cells (fibroblasts and endothelials cells) that
are likely to be affected by the pharmacologic treatment with CPX
in a cutaneous wound. After 24 hours of exposure to CPX, there
was a robust HIF-1a stabilization in both cell types in a dose-
dependent manner as detected by Western Blot (Figure 1A). CPX
was more potent than DFO in inducing HIF-1a, with 10 mM CPX
inducing comparable HIF-1a stabilization response compared to
10-fold higher 100 mM DFO. Primary diabetic fibroblasts
responded similarly with marked induction of HIF-1a after 24
hours of exposure to CPX (Figure 1A, B). We next investigated
whether CPX also induces the endogenous HIF-1 target gene
VEGF, which is an essential mediator of angiogenesis. We
confirmed that treatment with the same range of CPX concentra-
tions that increased HIF-1a led to a significant accumulation of
VEGF in the supernatant of both types of treated cell line cultures
and primary diabetic cell culture compared to the untreated
controls in a dose-dependent manner as measured by ELISA
(Figure 1C). CPX was also more potent than DFO in inducing
VEGF protein production. (Figure 1C).
CPX induces multiple angiogenic genes
Given our observation of increased HIF-1a and VEGF with
CPX treatment, we further explored the potential of CPX as a
therapeutic agent for angiogenesis by evaluating the expression
levels of other common angiogenesis-related genes. We next chose
to determine the effect of treatment with 10 mMC P Xf o r2 4h ou r s
in NIH3T3 cells in comparison to untreated cells on the multiple
other angiogenesis-related genes’ mRNA levels using quantita-
tive, real-time-polymerase chain reaction (QRT-PCR). This
experiment established that there was significant upregulation of
multiple other angiogenic genes (Figure 2A). These included
endogenous genes under direct regulation by HIF-1a such as
fibroblast growth factor (FGF)-2 and VEGF. In addition, there
was also 3 to 10-fold increase in the expression of multiple
angiogenic cytokines that are not known to be under direct
regulation HIF-1a including angiogenin (ANG), CX3CL1, and
proliferin. Elevated angiogenic gene expression was confirmed at
the protein level using the angiogenesis antibody array, where
multiple common angiogenesis-related proteins were over-
expressed in the supernatant of the treated cells compared to
that of untreated control cells (Figure 2B). Some differences were
noted between the levels of mRNA expression and protein
expression for genes, which may be attributed to timing
differences between gene and protein expression and possible
post-transcriptional mechanisms affecting mRNA stability and
protein degradation. Nonetheless, there was a clear trend toward
elevated angiogenic gene expression in cells treated with CPX at
both mRNA and protein levels.
CPX induces angiogenesis in vitro
Given that CPX treatment strongly induces multiple angiogenic
genes, we next examined the effect of CPX on the vasculature using
a short-term in vitro assay using human umbilical vein endothelial
cells (HUVEC cells). This assay evaluates the propensity of primary
endothelial cells to sprout and form three-dimensional structures
resembling capillaries in response to appropriate cues. To achieve a
statistically significant morphometric analysis of capillary density,
blood vessel branching points were counted in nine high power
fields. Compared to treatment with dimethyl sulfoxide (DMSO),
treatment with 10 mM CPX significantly increased the number of
branch points per field of view, indicating elevated angiogenesis.
When 10 ng/ml VEGF was co-administered with CPX, there was
slightly increasedtubule formationbycells compared to cells treated
with VEGF alone (Figure 2C).
Topical CPX application Enhances Wound Healing and
Angiogenesis in Diabetic Mice
Because CPX strongly induces angiogenic genes and endothelial
tubule formation in vitro, we next evaluated the potential therapeutic
efficacy of CPX in vivo using a humanized wound healing model in
leptin deficient type II diabetic db/db mice. By stenting the wounds
with silicone rings, mouse wounds heal primarily by granulation
tissue deposition similar to humans, rather than by contraction
which occurs in conventional mouse wound models [13].
Serial topical application every other day with 50 mM CPX on
the wounds of diabetic mice significantly enhanced the wound
healing response compared to the DMSO treated wounds. Fifty
mM dosing was chosen to approximate the 1–8% CPX concen-
tration currently available as dermal cream or nail lacquer
preparations for clinical usage. Topical treatment with CPX
accelerated wound closure compared to controls, with complete
closure occurring by day 14 post-wounding in CPX-treated mice
versus day 22 in DMSO vehicle-treated mice (*p,0.05)
(Figure 3A). No significant systemic side effects such as weight
loss or local side effects such as increased edema or allergic reaction
werenoted inCPX-treated mice. Interestingly,CPX-treated wound
beds appeared strikingly more red at day 10 post-wounding
compared to DMSO-treated control wounds due to the increased
angiogenesis in the CPX-treated wound beds, and this was
associated with an early re-epithelialization of the CPX-treated
wounds compared to control wounds (Figure 3A). The gross
observation of increased wound vascular density by CPX was
confirmed by histology, with evidence of enhanced angiogenesis
with a statistically significant 53% increase in the number of blood
vessels as measured by the number of CD31-positive cells in the
wound bed of CPX-treated animals relative to the number of blood
vessels in the wound bed of controlanimals (*p,0.05). (Figure 4A).
HIF-1a protein concentration was increased in skin tissue
lysates of wounds treated with CPX through postoperative day 4.
Western blot for HIF-1a demonstrate a significant increase in
protein concentration in wounds treated with CPX versus
unwounded untreated skin, wounded untreated skin, and vehicle
treated wounded skin (*p,0.01). (Figure 3B).
Histological analysis showed increased capillary density in
wounded skin treated with CPX. Capillary density was quantified
by software-assisted analysis of pixel number (Adobe Photoshop
software) per section of the wound bed after immunofluorescence
staining for endothelial cells with an anti-CD31 antibody.
(Figure 4A) Therapeutic angiogenesis induced by CPX in the
diabetic wounds resulted in a robust increase in the dermal
Ciclopirox Olamine in Diabetic Wound Healing
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wounds. (Figure 4B).
Discussion
Diabetic wounds remain a major challenge in current clinical
practice with often disappointing outcomes despite best available
care. Only two-thirds eventually heal, and up to 28% may result in
some form of amputation [14–16]. Insufficient angiogenesis has
been implicated in the abnormal wound healing that leads to
diabetic skin ulcers [17]. In this report, we show that the
antimycotic drug CPX is a potent inducer of therapeutic
angiogenesis via HIF-1a stabilization. Using a humanized diabetic
wound model, we demonstrate that serial topical application of
CPX caused significant acceleration of wound healing by inducing
improved angiogenic response.
Currently, there is little to no evidence to support the use of
topically applied products in the treatment of diabetic foot ulcers
in routine clinical practice [18]. Despite the relatively large
number of studies of growth factors, recombinant platelet derived
growth factor BB (PDGF-BB) is the only agent approved by FDA
for clinical use in diabetic ulcers, and outcomes from the use of this
agent have been disappointing [19]. Because pathogenesis of
diabetic ulcers is complex, application of a single growth factor
such as PDGF is likely an inadequate approach to accelerating the
repair of chronic diabetic wounds. Many growth factors essential
Figure 1. Effect of CPX treatment in vitro. (A) Treatment with 5–10 mM CPX for 24 hours on bEND.3 endothelial cell line, NIH3T3 cell line, and
primary diabetic fibroblasts stimulated HIF-1a activation in a dose-dependent manner (B) Densiometry data showing pixel density of Western blot
data calculated using ImageJ software. Pixel density is expressed as a ratio to b-actin and normalized to untreated cells. Astericks indicate statistically
significant increase in protein concentration relative to untreated controls. (*p,0.05) (C) Conditioned media of cells treated with 5–10 mM CPX for 24
hours led to a significant increase in VEGF expression as detected by ELISA in bEND.3, NIH3T3, and diabetic primary fibroblast cells. (*p,0.05).
doi:10.1371/journal.pone.0027844.g001
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(PDGF), fibroblast derived growth factor 2 (FGF-2), vascular
endothelial growth factor (VEGF), and stromal cell derived factor-
1 alpha (SDF-1a), are reduced in diabetic wounds [20–23].
Diminished production of HIF-1a and its target genes such as
VEGF are thought to contribute to insufficient angiogenesis that
results in impaired tissue repair in diabetes [21,23,24]. Therefore,
upregulation of the upstream transcription factor HIF-1a is
potentially a more effective therapeutic strategy compared to
single growth factor application. Furthermore, considering the
safety, costs, and ease of application, a pharmaceutical approach
to increasing HIF-1a would be the most practical and beneficial
solution.
In this study, a leptin deficient type II diabetic mouse model was
used to demonstrate positive effects of CPX on angiogenesis and
wound healing. Although some recent literature suggests that a
polygenic model of diabetes may better approximate the type II
diabetic human phenotype [25], the literature supporting the use
of a single model is limited, and all small animal models of diabetes
have limitations. The db/db leptin deficient mouse model was
chosen for these experiments due to its preeminence in the
literature as a well-established, reproducible model of diabetic
wound healing.[26]
CPX has previously been shown in the literature to induce
angiogenesis through the stabilization of HIF-1a and resultant
VEGF induction, both in vitro and in vivo.[12] Using a diabetic
excisional wound healing model, we confirmed these findings and
showed that CPX is capable of stabilizing HIF-1a and activating
many endogenous target genes important for wound healing such
as VEGF, FGF-2, and SDF-1. CPX was first developed to treat
fungal skin infections and vaginal candidiasis and currently has
well established efficacy for these indications [27]. Although its
exact mechanism of action is unknown, the high affinity of CPX
for trivalent metal cations, resulting in inhibition of the metal-
Figure 2. Downstream effects of CPX treatment in vitro. (A) QRT-PCR analysis on NIH3T3 cells treated with 10 mM CPX for 24 hours versus
untreated control. There were 3 to10-fold increases in the mRNA expression of multiple angiogenesis-related genes relative to that of untreated
control cells. Asterisks indicate *p,0.05. (B) Angiogenesis antibody array using condition media from NIH3T3 cells treated with 10 mM CPX for 24
hours versus condition media from untreated control cells. Membrane images of antibody array treated with condition media of treated and control
cells (top). Specific proteins captured on the array are labeled 1 to 8. Semi-quantitative profiles of proteins 1 to 8 on the angiogenesis antibody array
using reverse image scanning densitometry (bottom). There was a significant increase in the expression of multiple angiogenic proteins by NIH3T3
cells treated with CPX compared to untreated control cells. Asterisks indicate *p,0.05. (C) The ability of CPX (10 mM) in inducing in vitro tubule
formation with or without VEGF (10 ng/ml) treatment. Representative cell images showing field of view as indicated (left). The angiogenic effect was
quantified by counting the number of branch points per field of view (right). Endothelial cells treated with CPX (10 mM) increased the number of
branch point cells with or without concomitant VEGF (10 ng/ml) treatment compared to those cells treated with DMSO control (40X). White arrows
indicate examples of branch points (*p,0.05).
doi:10.1371/journal.pone.0027844.g002
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peroxides within the fungal cell, is thought to be the major
determinant of its antimycotic activity [27]. CPX is also a potent
iron chelator, and therefore can also indirectly inhibit PHD-2, the
key upstream negative regulatory gene in HIF-1 pathway that
requires iron as a cofactor [12,28]. Prolyl hydroxylase domain-2
(PHD-2) has additional HIF-independent functions in mediating
the angiogenic switch via negative regulation of nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-kB). [29] We
found that treatment with CPX not only led to increased HIF-1a
Figure 3. Topical CPX enhanced wound healing in diabetic mice. Full-thickness skin wounds on diabetic mice were treated topically with
50 mM CPX, DMSO as vehicle control, and no treatment every other day until wound closure. (A) Wound closure rate over time. There was a
significant acceleration of wound healing in the CPX treatment group (n=10; *p,0.05) (top). Representative photographs of wounds treated with
DMSO vehicle control, no treatment, or 50 mM CPX (bottom). Treatment with CPX healed wounds significantly faster with increased vascularity
(grossly represented in red color) in the wound bed compared to vehicle control. (B) Western blot showing statistically significant HIF-1a expression
in tissue lysates harvested from wounds treated with CPX compared to those harvested from unwounded untreated skin, untreated wounded skin,
and vehicle-treated wounded skin. (*p,0.01)
doi:10.1371/journal.pone.0027844.g003
Figure 4. Histological analysis of wounded skin. (A) Effects of CPX on wound vascularity. Wound sections were stained with an anti-CD31
antibody and detected with Fluor 594 (red). Software-assisted quantification of vessel density in the entire area of residual wounds at day 22, as
percent fluorescence. Wounds from CPX-treated mice had significantly higher vessel density compared with that from DMSO-treated mice (*p,0.05).
(B) Hematoxylin and Eosin stains of wound tissue after full closure at 22 days post-wounding (left). CPX-treated wounds have higher dermal cellularity
in the wound bed compared to DMSO-treated control wounds. The black box indicates the area of healed wound depicted under high power view.
Quantification of cellularity in the wound by counting total cell number per high-powered field views (10640) (right).
doi:10.1371/journal.pone.0027844.g004
Ciclopirox Olamine in Diabetic Wound Healing
PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27844protein availability and its downstream angiogenic genes but also
activated many NF-kB-dependent pro-angiogenic factors includ-
ing ANG, CX3CL1, CXCL1, and tissue factor. Therefore,
pharmacologic inhibition of PHD-2 may be a mechanism by
which CPX enhances the angiogenic response in the diabetic
environment, and this mechanism may be more effective than
gene transfer techniques aimed only at HIF-1a gain-of-function.
Although iron chelators have been shown to decrease
inflammation in the wound bed and accelerate wound closure, it
is also thought that large doses of these compounds can induce cell
death. [30] This dose response is important to consider when
designing clinical trials for the use of CPX and other iron chelators
in wound healing, as high doses may be more appropriate for the
treatment of hyper-proliferative states, such as malignancy.
Increased angiogenesis may allow for increased oxygen and
nutrient delivery to developing granulation tissue, which can have
other positive effects on wound healing, such as increased
migration, decreased apoptosis, and increased cell survival. For
example, in addition to allowing increased availability of HIF-1a
protein and activating other angiogenic factors in the wound bed,
CPX was found to increase dermal cellularity. During the
proliferative phase of wound healing, macrophages release factors
that stimulate granulation tissue formation. The fibrin clot is
replaced by highly vascular tissue made up of many different cell
types, including—but not limited to—fibroblasts and myofibro-
blasts. During remodeling, which can last a protracted period,
these cells remain active in the wound, as an avascular and
acellular scar develops. [31,32]
Compared to wild type mice, diabetic mice demonstrate
impaired healing for size-matched excisional wounds. Hematox-
ylin and Eosin stains of fully healed wounds demonstrate increased
dermal cellularity at day 22 in CPX treated wound beds, indicating
an increase in dermal proliferation and remodeling. This finding
suggests that at day 22, wounds treated with CPX are further along
in the proliferative and remodeling phases of wound healing than
untreated or vehicle control treated wounds.
Our finding that serial topical CPX treatment significantly
enhances healing of humanized diabetic wounds has significant
clinical implications. Linden et al. suggested that CPX may be
beneficial for skin wound healing based on the observation that
CPX induced angiogenesis in the chicken chorioallantoic
membrane [12]. However, to the best of our knowledge, no
published studies to date have evaluated the efficacy of CPX in the
treatment of diabetic wounds. Another iron chelator, DFO, used
systemically in the treatment of chronic iron overload, has been
shown to activate HIF-1a and enhance diabetic wound healing
when it is applied topically to the wound bed [23]. While CPX and
DFO share a similar mechanism of action (i.e. iron depletion),
CPX may be a more attractive candidate for pharmacologic
therapy for chronic diabetic wounds. CPX has already been
shown to be an effective treatment agent for onychomycosis in
diabetic patients due to its efficacy, excellent safety profile with
extremely low systemic absorption, and ease of use, which has
resulted in high patient compliance [33]. Diabetic patients are at
increased risk for dermatomycoses and onychomycoses, with
approximately one-third of diabetic patients affected [34].
Diabetic patients with onychomycosis have a substantially higher
risk of complications such as secondary foot infections, gangrene,
and foot ulcers compared with diabetic patients without onycho-
mycosis[33].Thus,havinga product thatis both fungicidal and safe
to use is beneficial to diabetic patients with chronic wounds. In
addition, a treatment that requires serial topical applicationrequires
that patient give attention to their wounds daily, which is ideal for
diabetic patients who should be examining their feet regularly to
monitor ulcer developments. Furthermore, because topical CPX
treatment is already well-established for the treatment of onycho-
mycosisand dermatomycoses, the potentialforCPX to heal chronic
diabetic wounds in humans could be evaluated in clinical trials
relatively quickly.
In conclusion, serial topical treatment with the antimycotic drug
CPX may be regarded as a promising novel therapeutic treatment
for diabetic ulcers. Additional human clinical trials will be required
to determine the clinical applicability of CPX treatment to
improve wound healing in diabetic patients.
Materials and Methods
Cell lines and culture
The mouse fibroblast cells NIH3T3 were cultured in Dubecco’s
Modified Eagle’s Medium (DMEM; high glucose) supplemented
with 10% bovine calf serum (Gibco) as described in the American
Type Culture Collection protocol. The mouse endothelial cells
bEND.3 were cultured in DMEM medium (high glucose)
supplemented with 10% fetal bovine serum (Gibco) as described
in the ATCC protocol. Human umbilical vein endothelial cells
were purchased from Lonza (C2517A). Cells were maintained in
culture in the supplier’s recommended complete medium
(Endothelial Cell Growth Medium-2) at 37uC, 5% CO2. The
maximum passage number used for experiments was six, and cells
were pre-cultured in serum free medium for 24 hr before
angiogenesis assay. CPX (5–10 mM) and deferoxamine (DFO;
100 mM) were purchased from Sigma and CPX was prepared in
dimethyl sulphoxide (DMSO; Sigma) for indicated experiments.
Isolation of primary diabetic dermal fibroblasts
Dorsal skin from adult diabetic db/db mice (BKS.Cg-Dock7
m +/+
Lepr
db/J, stock #000642; Jackson Laboratories) was excised and
used for the isolation of fibroblasts as reported previously [35].
Briefly, harvested skin tissues were washed with Betadine (Fisher
Scientific) and PBS, minced, then incubated in a collagenase/
dispase (Roche) mixture at 37uC with constant shaking for 3 hours
to obtain single cell suspensions. The primary diabetic fibroblasts
were cultured in DMEM medium supplemented with fetal bovine
serum (Gibco). The primary fibroblasts were passaged twice, then
treated with CPX, DMSO, or DFO.
Vascular endothelial growth factor (VEGF) enzyme-linked
immunosorbent assay (ELISA)
Quantikine murine VEGF ELISA kits (R&D Systems) were
used according to the manufacturer’s protocol. Briefly, VEGF
standards (1 to 1000 pg/mL) and samples were placed by pipette
into wells coated with antibody specific for mouse VEGF. After a
wash, an enzyme-linked polyclonal antibody specific for VEGF
was added to the wells. After a second wash, a substrate solution
was added. The absorbance of standards and samples was
measured spectrophotometrically at 450 nm with a wavelength
correction set to 570 nm using a microplate reader. VEGF
concentrations were calculated (in pg/mL) with the standard curve
via four parameter logistic (4-PL) curve-fit model using GraphPad
Prism (GraphPad Software, Inc.), and then adjusted for protein
concentrations. Total protein concentrations in each sample were
determined by the Bradford assay (Bio-Rad).
Western blotting
NIH3T3, bEND.3, and primary diabetic fibroblasts were
exposed to 5–10 mM CPX or 100 mM DFO for 24 hours as
specified. Cells were lysed in urea lysis buffer (9 M urea, 75 mM
Tris [pH 7.5], 150 mM ß-mercaptoethanol). Cells were sonicated
Ciclopirox Olamine in Diabetic Wound Healing
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Bradford assay (Bio-Rad). Denatured proteins were resolved on a
sodium dodecyl sulfate (SDS)-polyacrylamide gels and then trans-
ferred onto polyvinyl difluoride membranes. Primary antibodies
againstmouseHIF-1a(NB100–449; Novus Biological,Littleton, CO)
and b-actin (RB-9421, Thermo Scientific) were used for detecting the
corresponding proteins. Experiments on NIH3T3 cells, bEND.3
cells, and primary diabetic fibroblasts were performed three times.
Densitometry data was calculated using ImageJ software.
Quantitative reverse transcriptase-polymerase chain
reaction (RT-PCR) analysis
Total RNA from treated cells was extracted using the RNeasy
Plus Mini Kit (Qiagen) and reverse transcribed by the TaqMan
Reverse Transcription Reagents (Applied Biosystems). Real-time
quantitative PCR was run on the ABI Prism 7900HT Sequence
Detection System (Applied Biosystems) and Power SYBR Green
Master Mix (Applied Biosystems). PCR was performed by
denaturing at 95uC for 15 min, followed by 40 cycles of
denaturation at 95uC for 30 s and annealing at 60uC for 1 min.
All expression data were normalized to actin. All reactions were
run in triplicate. Two independent experiments were performed.
The sequences of primers used are listed in Table S1.
Angiogenesis Antibody Array
Proteome Profiler
TM Mouse Angiogenesis Antibody Array
(R&D Systems) was used according to the manufacturer’s
protocol. In brief, the nitrocellulose membranes were first
incubated in blocking buffer for 1 hr. A cocktail of biotin-labeled
antibodies against different individual angiogenesis-related pro-
teins was incubated with about 1 ml of conditioned media
prepared from NIH3T3 cells treated with or without 10 mM
CPX after normalization with equal amounts of total protein. The
sample and antibody mixture was then incubated with the
membrane overnight at 4uC. After multiple washings to remove
unbounded mateials, the membranes were incubated with
horseradish peroxidase (HRP) conjugated streptavidin for 1 hr at
room temperature. After washing the membranes, the signals were
detected by ECL system (Amersham Pharmacia Biotech Ayles-
bury, UK). The array image was then semiquantitated by reverse
image scanning densitometry (Adobe Photoshop CS4, Adobe
Systems). The array was run in duplicates.
In vitro angiogenesis assay
Approximately 2610
4 human umbilical vein endothelial cells
(HUVEC) in 50 ml serum free medium were seeded into each well
of 96-well plates. The plate wells were coated with 40 mlo fB D
Matrigel Matrix which was polymerized for 30 min at 37uC.
Growth factor (10 ng/ml VEGF) and/or 10 mM of CPX were
added to the cell cultures. After 16 hours incubation, the cells were
labeled with 8 mg/ml Calcein AM (BD) and were evaluated for
capillary tubule formation.
Wound Model
All experiments were performed in accordance with the
Stanford University Animal Care and Use Committee Guidelines
(protocol ID #21308). Diabetic db/db mice (12-15 weeks old,
BKS.Cg-m +/+ Lepr
db, stock #000642; Jackson Laboratories)
were housed five per cage in a 12-h light/dark cycle and provided
ad libitum with standard food and water.
After depilation, two 6-mm full-thickness wounds extending
through the panniculus carnosus were made on dorsa of mice as
previously described [13]. A donut-shaped 12 mm silicone splint
(Invitrogen) was placed and fixed to the skin with cyanoacrylate glue
and interrupted 6–0 nylon sutures so that the wound was centered
within the splint. The animals were randomly divided into two
groups with 5 animals (and, therefore, 10 wounds) per group.
Ten mL of 50 mMCPX or DMSO vehicle wasplaced topicallyonto
the openwound bed everyotherday untilclosure.A Tegaderm(3M)
dressing was placed over the wounds after each topical application,
and theanimalswere housedindividually.Digitalphotographsofthe
wounds were taken every other day until closure. Time to wound
closure was defined as the time at which the wound bed was
completelyre-epithelizedandfilledwith newtissue.Wound area was
quantified by tracing the wound margins and calculated as a percent
area of the original wound size using ImageJ software (NIH), with
scaling normalized to the circular reference of the splint.
To evaluate tissue HIF-1a levels, wounds treated with CPX or
DMSO were harvested along with4-mm rim of normal skinaround
the wounds on day four post wounding. Unwounded untreated skin
was harvested in a similar fashion, with the same diameter of tissue
excised. Tissues were minced and homogenized in urea lysis buffer.
HIF-1a expression was probed by Western Blot as described above.
These experiments were repeated four times.
Histology, Immunohistochemistry Staining, and
Evaluation
After fixation in 4% paraformaldehyde, tissue samples were
embedded in optimal cutting temperature (O.C.T.) and sliced into
sections of 8 mm thickness using a cryostat. Every tenth section was
stained with hematoxylin and eosin (H&E). Four high-powered
fields (10640) of wound areas were chosen from each slide, and
total number of cells per field of view was counted. Vascular
density was detected using a CD31 monoclonal antibody (1:500
dilution, BD Biosciences) with a secondary Alexa-Fluor 594-linked
anti-rat IgG antibody (1:1000 dilution, Invitrogen). Vessel density
was quantified by assessing total number of red fluorescent-labeled
vessels normalized to the entire wound area at 400x magnification,
using Image J software. The data represent average values from
nine high-power fields from three independent mouse wounds.
Statistical Analysis
All data are expressed as mean 6 SEM. Student’s t test or
Wilcoxon rank sum tests were used to determine significance. A p
value ,0.05 was considered statistically significant.
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